New email dellery1@gmail.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What's Behind the Run-Up at Rexahn?
http://www.fool.com/investing/general/2011/01/27/whats-behind-the-run-up-at-rexahn.aspx
What's Behind the Run-Up at Rexahn?
http://www.fool.com/investing/general/2011/01/27/whats-behind-the-run-up-at-rexahn.aspx
Congrats!!!
I think I will just watch for a bit. GL
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=59272760
BoinG!
Ambac rehabilitation plan approved
2:57 pm ET 01/25/2011- MarketWatch Databased News
SAN FRANCISCO (MarketWatch) -- A rehabilitation plan proposed by the regulator of Ambac Financial Group's main bond-insurance subsidiary was approved by a Wisconsin Circuit Court on Tuesday.
Shares of the holding company, Ambac Financial Group, jumped more than 50% to 19 cents in afternoon trading. The holding company filed for bankruptcy protection from creditors last year. Read about the collapse here.
A spokesman for the company confirmed the Wisconsin court decision on Tuesday.
Originally an insurer of municipal bonds, Ambac sold guarantees on billions of dollars of mortgage-backed securities and more complex vehicles known as collateralized debt obligations, or CDOs. When the housing meltdown hit, many of these securities turned toxic, leaving Ambac with heavy losses.
In March, the Wisconsin insurance commissioner -- the regulator of the company's main unit, Ambac Assurance -- seized the most troubled parts of the business to protect hundreds of billions of dollars in muni-bond guarantees. Read more about the seizure last year.
Policy holders with guarantees on more than $60 billion worth of soured assets like residential mortgage-backed securities and CDOs were put into a so-called segregated account.
Some of these policy holders sued, arguing that they shouldn't be treated differently from other Ambac policy holders. Read about the legal battle and how hedge funds get stuck paying premiums to Ambac.
glta
I aint got SHIP but they are looking cheap?
These 7 Stocks Are Starting to Look Pretty Cheap
http://www.fool.com/investing/general/2011/01/24/these-7-stocks-are-starting-to-look-pretty-cheap.aspx
Now you made me cry
RNN
Rexahn Pharmaceuticals Enrolls First Patient in Serdaxin® Phase IIb Clinical Trial
Press Release Source: Rexahn Pharmaceuticals, Inc. On Tuesday January 25, 2011, 8:00 am
ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled the first patient in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD). The randomized, double blind, and placebo-controlled study will recruit up to 300 patients and will be conducted at 40 sites in the United States. Serdaxin will be administered as an oral, extended release tablet. Patient enrollment will occur through the first half of 2011, with preliminary data expected in late 2011.
Rick Soni, President of Rexahn, commented, “This clinical milestone represents another important advance in the development of Serdaxin. Data from our Phase IIa study in MDD suggest that Serdaxin has the potential to improve symptoms of depression without the side effects commonly associated with currently marketed antidepressants, and we look forward to further assessing Serdaxin in patients with MDD.”
About Serdaxin®
Serdaxin® is a potential market-leading CNS neuroprotective agent and antidepressant. Rexahn is currently investigating Serdaxin as a treatment for depression, in a large Phase II clinical trial. Serdaxin may achieve greater and broader therapeutic coverage and appears to be safe and well tolerated without the appearance of serious side effects that are commonly linked to currently marketed antidepressant drugs, such as selective serotonin uptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), and tricyclic antidepressants (TCA). Serdaxin has a well-established, excellent human safety profile. In preclinical studies, Serdaxin had onset of action in less than two days.
Based on its novel mechanism as a dual serotonin and dopamine enhancer, it is a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses, such as Parkinson’s disease (PD). Serdaxin has the potential to address both non-motor and motor events of PD by serving as a neuroprotective agent and addressing loss of dopaminergic neurons that lead to loss of control of movements; and further, enhancing serotonin and dopamine levels that are involved in depression and mood disorders. Rexahn has multiple clinical programs planned for investigating Serdaxin in the treatment of anxiety disorders, Parkinson’s disease, Alzheimer’s disease and neurodegenerative illnesses, neuroprotection and biodefense uses.
Rexahn Pharmaceuticals Enrolls First Patient in Serdaxin® Phase IIb Clinical Trial
Rexahn Pharmaceuticals Enrolls First Patient in Serdaxin® Phase IIb Clinical Trial
Press Release Source: Rexahn Pharmaceuticals, Inc. On Tuesday January 25, 2011, 8:00 am
ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled the first patient in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD). The randomized, double blind, and placebo-controlled study will recruit up to 300 patients and will be conducted at 40 sites in the United States. Serdaxin will be administered as an oral, extended release tablet. Patient enrollment will occur through the first half of 2011, with preliminary data expected in late 2011.
Rick Soni, President of Rexahn, commented, “This clinical milestone represents another important advance in the development of Serdaxin. Data from our Phase IIa study in MDD suggest that Serdaxin has the potential to improve symptoms of depression without the side effects commonly associated with currently marketed antidepressants, and we look forward to further assessing Serdaxin in patients with MDD.”
About Serdaxin®
Serdaxin® is a potential market-leading CNS neuroprotective agent and antidepressant. Rexahn is currently investigating Serdaxin as a treatment for depression, in a large Phase II clinical trial. Serdaxin may achieve greater and broader therapeutic coverage and appears to be safe and well tolerated without the appearance of serious side effects that are commonly linked to currently marketed antidepressant drugs, such as selective serotonin uptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), and tricyclic antidepressants (TCA). Serdaxin has a well-established, excellent human safety profile. In preclinical studies, Serdaxin had onset of action in less than two days.
Based on its novel mechanism as a dual serotonin and dopamine enhancer, it is a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses, such as Parkinson’s disease (PD). Serdaxin has the potential to address both non-motor and motor events of PD by serving as a neuroprotective agent and addressing loss of dopaminergic neurons that lead to loss of control of movements; and further, enhancing serotonin and dopamine levels that are involved in depression and mood disorders. Rexahn has multiple clinical programs planned for investigating Serdaxin in the treatment of anxiety disorders, Parkinson’s disease, Alzheimer’s disease and neurodegenerative illnesses, neuroprotection and biodefense uses.
Rexahn Pharmaceuticals Enrolls First Patient in Serdaxin® Phase IIb Clinical Trial
RNN
Cool lets make some money
My average is 1.19 now.
RNN
Teva Pharmaceutical Increases Its Investment in Rexahn for the Continued Research and Development of the Pre-Clinical Anti-Cancer Compound, RX-3117
http://finance.yahoo.com/news/Teva-Pharmaceutical-Increases-bw-2736591097.html?x=0&.v=1
$BDI....tick....tock...
For ships sake that better be a bottom.
ARIA
Positive Phase III Results May Mean Big Payday for Ariad
http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=57101
DEPO
Looks like the Depo PPS roller coaster will continue. It did move up a bit near the end of AH trading after the conference call.
any thoughts?
5 Precious Metals Stocks You 'Beta' Avoid
http://stocks.investopedia.com/stock-analysis/2011/5-Precious-Metals-Stocks-You-Beta-Avoid-HL-CDE-GDXJ-SWC-NG0111.aspx?partner=YahooSA
Compare the BDI to various dry bulk carrier charts. When the BDI was at its 2 year high most shippers were only 20% higher.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=50277253
RNN good, I still own it, I dont know why, but good
Hecla Mining Shares Plunged: What You Need to Know
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of silver and gold producer Hecla Mining (NYSE: HL) plunged as much as 10% on heavy volume Tuesday on weak precious-metal prices.
So what: A fervent return of investors' appetite for risk sent silver and gold prices slumping Tuesday, with miners Hecla, U.S. Gold (NYSE: UXG), and Silvercorp (NYSE: SVM) among the biggest losers on the New York Stock Exchange. At the time of this writing, more than 18 million Hecla shares have traded, versus its three-month average of 13.2 million shares.
Now what: I wouldn't rush into Hecla just yet. Even with today's plunge, it's still up more than 100% over the past six months, and it trades at a lofty-ish 35-plus P/E. Of course, at the right price, Hecla is a low-debt, free-cash-flow-generating, well-managed inflation fighter that Fools should certainly consider.
NEW YORK (AP) -- A look at the 10 biggest percentage decliners on New York Stock Exchange at 1 p.m.:
First Majestic Silver Corp. fell 12.3 percent to $13.68.
Hecla Mining Co. fell 8.7 percent to $10.26.
US Gold Corp. fell 8.7 percent to $7.25.
RealD Inc. fell 8.5 percent to $23.63.
Agree Realty Corp. fell 8.2 percent to $23.93.
Darling International Inc. fell 8.2 percent to $12.21.
MarineMax Inc. fell 7.5 percent to $8.73.
Federal Agricultural Mortgage Corp. class A fell 7.4 percent to $12.18.
Movado Group Inc. fell 7.4 percent to $14.96.
Silvercorp Metals Inc. fell 7.3 percent to $12.09.
Go Amos!
Your a precious metals guy what do you make of this?
Hecla Mining Shares Plunged: What You Need to Know
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of silver and gold producer Hecla Mining (NYSE: HL) plunged as much as 10% on heavy volume Tuesday on weak precious-metal prices.
So what: A fervent return of investors' appetite for risk sent silver and gold prices slumping Tuesday, with miners Hecla, U.S. Gold (NYSE: UXG), and Silvercorp (NYSE: SVM) among the biggest losers on the New York Stock Exchange. At the time of this writing, more than 18 million Hecla shares have traded, versus its three-month average of 13.2 million shares.
Now what: I wouldn't rush into Hecla just yet. Even with today's plunge, it's still up more than 100% over the past six months, and it trades at a lofty-ish 35-plus P/E. Of course, at the right price, Hecla is a low-debt, free-cash-flow-generating, well-managed inflation fighter that Fools should certainly consider.
NEW YORK (AP) -- A look at the 10 biggest percentage decliners on New York Stock Exchange at 1 p.m.:
First Majestic Silver Corp. fell 12.3 percent to $13.68.
Hecla Mining Co. fell 8.7 percent to $10.26.
US Gold Corp. fell 8.7 percent to $7.25.
RealD Inc. fell 8.5 percent to $23.63.
Agree Realty Corp. fell 8.2 percent to $23.93.
Darling International Inc. fell 8.2 percent to $12.21.
MarineMax Inc. fell 7.5 percent to $8.73.
Federal Agricultural Mortgage Corp. class A fell 7.4 percent to $12.18.
Movado Group Inc. fell 7.4 percent to $14.96.
Silvercorp Metals Inc. fell 7.3 percent to $12.09.
Coydog said he would concentrate on his other investments and wait for the market to become more stable. We hope he comes back to trade soon and share his money making wisdom and of course the boogie woogie piano man (starboy) is always welcome here
Please accept with no obligation, implied or explicit, my best wishes for an environmentally conscious, socially responsible, low-stress, non-addictive, gender-neutral celebration of the winter solstice holiday, practiced within the most enjoyable traditions of the religious persuasion of your choice, or secular practices of your choice, with respect for the religious/secular persuasion and/or traditions of others, or their choice not to practice religious or secular traditions at all. I also wish you a fiscally successful, personally fulfilling and medically uncomplicated recognition of the onset of the generally accepted calendar year 2011 but not without due respect for the calendars of choice of other cultures whose contributions to society have helped make America great. Not to imply that America is necessarily greater than any other country nor the only America in the Western Hemisphere . Also, this wish is made without regard to the race, creed, color, age, physical ability, religious faith or sexual preference of the wishee.
Wall Street Breakfast: Must-Know News
http://seekingalpha.com/article/242945-wall-street-breakfast-must-know-news
SEC probes U.S.-listed Chinese firms. The SEC has reportedly begun to investigate Chinese companies listed on U.S. stock exchanges through reverse takeovers, after hundreds of Chinese companies gained a U.S. listing by merging with dormant shell companies. As part of the investigation, the SEC is targeting individual Chinese companies for accounting violations and lax auditing practices, and is also looking into how U.S. accountants, bankers and lawyers may have facilitated the process.
chalk one up for the SEC
Anyone know why the pictures in forwards sent via Google Chrome dont appear or appear as a box?. I talked my Dad into switching to GC from AOL and have no clue what he is doing wrong
DryShips Strengthening Liquidity
Zacks Equity Research, On Monday December 6, 2010, 3:25 pm EST
http://finance.yahoo.com/news/DryShips-Strengthening-zacks-566836079.html?x=0&.v=1
DryShips Inc. (NasdaqGS: DRYS - News) has decided to sell $500 million worth of shares of its wholly own subsidiary Ocean Rig UDW Inc. through a private placement. The main purpose of this share offering is to finance the construction costs of the ultra deepwater newbuilding drillships under construction at Samsung Shipyard in South Korea and to exercise the option to build more ultra deepwater drillships. The private placement will reduce Dryships’ holding in Ocean Rig to around 78%-80%.
DryShips recently completed its equity offering from which it raised gross proceeds of $350 million. For this the company sold 79.2 million of shares which raised its total outstanding common shares by 27%. Net proceeds from this transaction were around $342 million.
However, the company’s new private placement will not increase its total share count. Furthermore, DryShips also secured a $325 million Senior Secured Bridge Loan Facility from an international lender.
Together these three financing arrangement will be sufficient to pay approximately $1.1 billion the first two drillship newbuilds. Last September, DryShips won a $135 million contract from a U.S.-based oil company to explore for energy off the coast of West Africa for 300 days for its first newbuilid drillship. The initial contract was to drill four wells of Vanco Overseas Energy.
Last October, the company gets an extension of this contract. The extension will add another well for drilling for a total contract size of $160 million. The project is expected to commence in the first or second quarter of 2011. DryShips further stated that this contract may be extended for another year.
On November 29, Ocean Rig signed a $77 million contract with Borders & Southern Petroleum Plc for a 2-well exploration and drilling pact in the offshore Falkland Islands area for a period of 90 days, beginning in the fourth quarter of 2011. There are three further optional wells that could extend the contract by 135 days.
DryShips is gradually converting itself as an ultra-deep water drilling company rather than continuing as a simple drybulk cargo operator. The acquisition of Ocean Rig turned out a major positive.
Ocean Rig’s asset and contract portfolio diversified DryShips’ assets and sources of cash flow. Furthermore, Ocean Rig’s operational expertise provided DryShips with the necessary platform to compete in the ultra-deep water drilling sector.
We maintain our long-term Outperform recommendation for DryShips. Nevertheless, drybulk shipping industry is highly competitive and fragmented. For that any individual operator controls very little pricing power in the market.
We believe this is the reason for DryShips to currently have a short-term Zacks #3 Rank (Hold). DryShips mainly compete with Diana Shipping Inc. (NYSE: DSX - News), Genco Shipping & Trading Ltd. (NYSE: GNK - News), and Excel Maritime Carriers Ltd. (NYSE: EXM - News).
That sounds good! I dont remember any bars around there. I believe they had weird "brown bag" laws.
Go Marilyn !!!